45 / 52
45
Los anti-VEGF y su aplicación en patologías oculares
central retinal vein occlusion: six-month
primary end point results of a phase III study.
Ophthalmology. 2010 Jun;117(6):1124-1133
33. Heier J., Campochiaro P., Yau L., Raroj N.,
Rubio R., Lai P. Ranibizumab for macular
edema due to retinal vein occlusions:
long-term follow-up in the HORIZON trial.
Ophthalmology 2012; 119(4): 802-809
34. Boyer D., Heier J., Brown D., et al. Vascular
Endothelial Growth Factor Trap-Eye for
Macular Edema Secondary to Central Retinal
Vein Occlusion Six-Month Results of the
Phase 3 COPERNICUS Study Ophthalmology
2012;119:1024–1032
35. Heier J., Clark W., Boyer D., et al Intravitreal
aflibercept injection for macular edema due to
central retinal vein occlusion: two-year results
from the COPERNICUS study. Ophthalmology
2014 Jul; 121(7): 1414-1420
36. Holz F., Roider J., Ogura., et al VEGF Trap-Eye
for macular oedema secondary to central
retinal vein occlusion: 6-month results of the
phase IIIGALILEO study. Br J Ophthalmol 2013
Mar; 97(3): 278-84
37. Ogura Y., Roider J., Korobelnik J., et al for
GALILEO study group Intravitreal aflibercept
for macular edema secondary to central
retinal vein occlusion: 18-month results of
the phase 3 GALILEO study. Am J Ophthalmol
2014; 158(5): 1031-8
38. Campochiaro P., Clark W., Boyer D., Heier J., et
al Intravitreal Aflibercept for Macular Edema
Following Branch Retinal Vein Occlusion
The 24-Week Results of the VIBRANT Study.
Ophthalmology 2015;122:538-544
39. Clark W., Boyer D., Heier J., Brown D., et al
Intravitreal Aflibercept for Macular Edema
Following Branch Retinal Vein Occlusion:
52-Week Results of theVIBRANT Study.
Ophthalmology 2016 Feb; 123(2):330-6
40. Wong T., FerreiraA., Hughes R., Carter G.,
Mitchell P. “Epidemiology and disease burden
of pathologic myopia and myopic choroidal
neovascularization: an evidence-based
systematic review,” Am J Ophthalmology 2014,
vol. 157 (1): 12-25
41. Tufail A., Narendran N., Patel P., Sivaprasad
S., et al Ranibizumab in Myopic Choroidal
Neovascularization: The 12-Month Results
from the REPAIR Study Ophthalmology 2013;
120(9): 1944-5
42. Wolf S., Balciuniene V., Laganovska G., et al
for RADIANCE study group. RADIANCE: a
randomized controlled study of ranibizumab
in patients with choroidal neovascularization
secondary to pathologic myopia.
Ophthalmology 2014; 121(3):682-92
43. Ikuno Y., Ohno-Matsui K., Wong T., et al
on behalf of the MYRROR investigators.
Intravitreal Aflibercept Injection in Patients
with Myopic Choroidal Neovascularization
The MYRROR Study. Ophthalmology
2015;122:1220-1227
44. Wong T., Ohno-Matsui K., Leveziel N., et al.,
“Myopic choroidal neovascularisation: current
concepts and update on clinical management,”
BJO 2015; 99(3): 289–296.